AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04577430
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The loading dose with 0.5 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
Trial: NCT04577430
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The loading dose with 1 μg/kg, maintenance dose with 0.5 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
Trial: NCT04577430
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The loading dose with 1 μg/kg, maintenance dose with 1 μg/kg of Dexmedetomidine is used to observe the effect on the electrophysiology of the patients' hearts
Trial: NCT01456169
Drug: Azilsartan medoxomil/placebo
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil and placebo to chlorthalidone combination tablets
Trial: NCT03013959
Drug: Pranoprofen
RxNorm normalized name: pranoprofen
DrugBank: Pranoprofen (DB13514)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
Trial: NCT03662789
Drug: Iron Isomaltoside 1000
RxNorm normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT02159976
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40mg bid
Trial: NCT02159976
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1000mg bid
Trial: NCT02159976
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 500mg tid
Trial: NCT02159976
Drug: Bismuth
RxNorm normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth 600mg bid
Trial: NCT00647907
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
Trial: NCT01165294
Drug: ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
Trial: NCT04331470
Drug: Levamisole Pill + Budesonide+Formoterol inhaler
RxNorm normalized name: budesonide / formoterol Inhalant Product
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole 50 mg tablet has to be taken 1-2 tablets every 8 hours Budesonide+Formoterol has to be inhaled 1-2 puff every 12 hours
Trial: NCT02724111
Drug: sufficient dose of rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02724111
Drug: sugammadex 10 min after position change
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01562678
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
Trial: NCT04331470
Drug: Lopinavir/Ritonavir + hydoxychloroquine
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Hydroxy Chloroquine 200mg single dise Lopinavir/Ritonavir 2 tablets every 12 hours
Trial: NCT00087269
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01061229
Drug: Homeopathic drug C12
RxNorm normalized name: C12:0
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
Trial: NCT01593124
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
Trial: NCT01593124
Drug: Nonoxynol-9
RxNorm normalized name: Nonoxynol-9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
Trial: NCT04574401
Drug: IS-002
RxNorm normalized name: IS-5MN
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of IS-002 Investigational Drug
Trial: NCT02259946
Drug: BI 1744 CL
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02259946
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04407988
Drug: Pyrotinib Maleate plus Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
Trial: NCT03920254
Drug: TD-1473 Dose C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See Arm description
Trial: NCT03263624
Drug: Tazarotene Cream 0.1%
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tazarotene cream 0.1% once daily
Trial: NCT00509938
Drug: human lactoferrin peptide 1-11
RxNorm normalized name: lactoferrin (synthetic human)
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
Trial: NCT02058251
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
Trial: NCT01374191
Drug: onabotulinum toxin type-A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 1 injection of Btx-A
Trial: NCT01374191
Drug: 2nd phase - onabotulinum toxin type-A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 2 - 3 injections of Btx-A, specific to patient pain recurrence
Trial: NCT00360672
Drug: Revlimid
RxNorm normalized name: Revlimid
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
Trial: NCT03148795
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg daily
Trial: NCT00422240
Drug: Adapalene/Benzoyl Peroxide
RxNorm normalized name: ADAPALENE/BENZOYL PEROXIDE
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
Trial: NCT00422240
Drug: Adapalene Gel, 0.1%
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1% of adapalene gel topically daily in the evening for 12 Weeks.
Trial: NCT00422240
Drug: Benzoyl Peroxide Gel 2.5%
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
Trial: NCT00422240
Drug: Gel Vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
Trial: NCT01680939
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.2-0.5 mg/kg PO q4h
Trial: NCT02341404
Drug: 2-hydroxyflutamide (2-HOF)
RxNorm normalized name: N-Hydroxyacetamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two components are mixed, transferred to a syringe and administered with injection into the prostate
Trial: NCT02134717
Drug: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks
RxNorm normalized name: maraviroc 300 MG
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00554450
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, Oral, once daily
Trial: NCT01249092
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
Trial: NCT03449069
Drug: MSC-AFP
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
Trial: NCT02380742
Drug: lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
Trial: NCT00751491
Drug: Adenosin
RxNorm normalized name: Adenosin
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary Adenosin 50 microg;
Trial: NCT00751491
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel 300/600 mg
Trial: NCT00802919
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varenicline 1-2 mg/day
Trial: NCT00802919
Drug: Placebo for varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00091234
Drug: gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01714557
Drug: Piperacillin
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.0g q8h 3-5 days
Trial: NCT01714557
Drug: Piperacillin-tazobactam combination product
RxNorm normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4.5g q8h 3-5 days
Trial: NCT02223338
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
Trial: NCT00580073
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
Trial: NCT03518112
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT or IV
Trial: NCT03518112
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO or IV
Trial: NCT03518112
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00778739
Drug: CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL
DrugBank: Cefprozil (DB01150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01837277
Drug: Dolutegravir 50 mg
RxNorm normalized name: dolutegravir 50 MG
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Use of Dolutegravir -based regimens: patients will receive a Dolutegravir -based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
Trial: NCT01837277
Drug: Efavirenz-based regimens
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
Trial: NCT00880607
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine injection is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain.
Trial: NCT04870502
Drug: Controlled ovarian stimulation by Combined Clomiphene Citrate and Ubiquinol Versus hMG
RxNorm normalized name: Clomiphene Citrate
DrugBank: Ubiquinol (DB11340)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In group A, controlled ovarian stimulation (COS) was done by Clomiphene Citrate (Fertab® 50 mg tablets, Zynova. SITCO Pharma.) as 150 mg (3 tablets) daily for 5 days (from 2nd day till 6th day of the cycle) together with Ubiquinol (active form of Coenzyme Q10) starting from 2nd day till the day of human Chorionic Gonadotropin (hCG) triggering in a dose of 100 mg capsules orally once daily, immediately after meal (Nutraquinol®; Jamjoom Pharma Nutraceuticals). In group B, Human Menopausal Gonadotropins (hMG) (Merional® 75 I.U. vials, IBSA.) IM was given from 2nd day of the cycle in a dose ranging from 75 to 225 IU according to the patient's response. Patients were instructed not to take any non-study drugs during the whole study period.
Trial: NCT00880607
Drug: Extended Release Epidural Morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
Trial: NCT01025297
Drug: Interleukin-7
RxNorm normalized name: interleukin-7
DrugBank: Interleukin-7 (DB11997)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 dose levels: 3, 10 \& 20 µg/kg. 4 administrations, 1 per week
Trial: NCT01190020
Drug: Lubiprostone
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
Trial: NCT01190020
Drug: Lubiprostone Control
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
Trial: NCT00570310
Drug: Comparator: pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
Trial: NCT02481791
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
Trial: NCT00307944
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02451865
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00909506
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1\~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3\~24 weeks.
Trial: NCT00909506
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1\~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3\~24 weeks (metformin 500 mg \* twice a day = 1000 mg per day).
Trial: NCT00988988
Drug: AGEE cream
DrugBank: iota-Carrageenan (DB15304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
Trial: NCT02451865
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01105936
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 665 mg sustained release paracetamol caplets
Trial: NCT00033592
Drug: bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00033592
Drug: nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01841489
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
Trial: NCT01841489
Drug: Treatment D
RxNorm normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1600 mg GS-9973 (Formulation 2)
Trial: NCT01841489
Drug: Treatment E
RxNorm normalized name: Benzoyl Peroxide 10% Topical application Cream [ACNE TREATMENT EXTRA STRENGTH]
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole